BRPI0517932A8 - Muteína humana de beta-interferon, polinucleotídeo, vetor de expressão, célula animal, método para preparação de referida muteína e composição farmacêutica compreedendo a mesma - Google Patents
Muteína humana de beta-interferon, polinucleotídeo, vetor de expressão, célula animal, método para preparação de referida muteína e composição farmacêutica compreedendo a mesmaInfo
- Publication number
- BRPI0517932A8 BRPI0517932A8 BRPI0517932A BRPI0517932A BRPI0517932A8 BR PI0517932 A8 BRPI0517932 A8 BR PI0517932A8 BR PI0517932 A BRPI0517932 A BR PI0517932A BR PI0517932 A BRPI0517932 A BR PI0517932A BR PI0517932 A8 BRPI0517932 A8 BR PI0517932A8
- Authority
- BR
- Brazil
- Prior art keywords
- mutein
- beta
- polynucleotide
- preparing
- pharmaceutical composition
- Prior art date
Links
- 102000003996 Interferon-beta Human genes 0.000 title abstract 5
- 108090000467 Interferon-beta Proteins 0.000 title abstract 5
- 210000004102 animal cell Anatomy 0.000 title 1
- 239000013604 expression vector Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 title 1
- 108091033319 polynucleotide Proteins 0.000 title 1
- 239000002157 polynucleotide Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2004-0088196 | 2004-11-02 | ||
KR1020040088196A KR100781666B1 (ko) | 2004-11-02 | 2004-11-02 | 인간 인터페론-베타 변이체 |
PCT/KR2005/003665 WO2006049423A1 (en) | 2004-11-02 | 2005-11-02 | Human interferon-beta mutein |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0517932A BRPI0517932A (pt) | 2008-10-21 |
BRPI0517932A8 true BRPI0517932A8 (pt) | 2018-05-02 |
BRPI0517932B1 BRPI0517932B1 (pt) | 2021-10-19 |
Family
ID=36319397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0517932-7A BRPI0517932B1 (pt) | 2004-11-02 | 2005-11-02 | Muteína humana de beta-interferon, polinucleotídeo, vetor de expressão, célula animal, método para preparação de referida muteína e composição farmacêutica compreedendo a mesma |
Country Status (11)
Country | Link |
---|---|
US (1) | US8101716B2 (pt) |
EP (1) | EP1809661B1 (pt) |
JP (1) | JP4637913B2 (pt) |
KR (1) | KR100781666B1 (pt) |
CN (1) | CN101111519B (pt) |
AT (1) | ATE509951T1 (pt) |
BR (1) | BRPI0517932B1 (pt) |
DK (1) | DK1809661T3 (pt) |
ES (1) | ES2369088T3 (pt) |
PT (1) | PT1809661E (pt) |
WO (1) | WO2006049423A1 (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2576030A1 (en) * | 2004-08-09 | 2006-02-23 | Alios Biopharma Inc. | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same |
MX2009011870A (es) | 2007-05-02 | 2009-11-12 | Ambrx Inc | Polipeptidos de interferon beta modificados y usos de los mismos. |
CN102260344A (zh) * | 2010-05-26 | 2011-11-30 | 重庆富进生物医药有限公司 | 缺失型人β干扰素及其重组制备 |
BR112014007766B1 (pt) * | 2011-10-01 | 2022-05-10 | Glytech, Inc | Polipeptídeo glicosilado, método para fabricação do mesmo e composição farmacêutica |
DK2982686T3 (en) | 2013-03-29 | 2018-10-08 | Glytech Inc | POLYPEPTIDE WITH SIALYLED SUGAR CHAIN CONNECTED |
ES2736503T3 (es) * | 2014-04-04 | 2020-01-02 | Ares Trading Sa | Nuevos análogos de la proteína IFN beta |
WO2016013697A1 (ko) * | 2014-07-24 | 2016-01-28 | 에이비온 주식회사 | 인터페론-베타 변이체의 폴리에틸렌글리콜 배합체 |
KR101671501B1 (ko) * | 2014-07-24 | 2016-11-03 | 에이비온 주식회사 | 페길화된 인터페론-베타 변이체 |
KR101838919B1 (ko) * | 2015-03-03 | 2018-03-15 | 에이비온 주식회사 | 인간 인터페론-베타 변이체가 접합된 면역사이토카인 및 이의 제조방법 |
US20210009720A1 (en) * | 2015-03-03 | 2021-01-14 | Genopharm Inc. | Human interferon-beta variant conjugated immunocytokine and method for preparing same |
WO2016163764A2 (ko) * | 2015-04-07 | 2016-10-13 | 에이비온 주식회사 | 인터페론 베타 변이체의 안정화 제제 |
KR102666000B1 (ko) | 2016-07-29 | 2024-05-14 | 서울대학교 산학협력단 | cFLIP siRNA를 포함하는 인터페론 베타 저항성 암 질환 치료용 또는 감작용 조성물 |
KR101943160B1 (ko) | 2016-10-06 | 2019-01-30 | 에이비온 주식회사 | 인터페론 베타 변이체의 안정화 제제 |
KR101955366B1 (ko) | 2017-06-02 | 2019-03-07 | 인제대학교 산학협력단 | 인터페론 베타-엘라스틴 재조합 단백질 및 이의 생산방법 |
CN108117595B (zh) * | 2018-02-28 | 2020-06-26 | 中国科学院微生物研究所 | 一种犬α干扰素的制备及其应用 |
KR20210021861A (ko) * | 2019-08-19 | 2021-03-02 | (주)제노팜 | 사람 표피성장인자수용체 2 양성 암을 치료하기 위한 인터페론-베타 변이체 면역사이토카인의 용도 및 환자 선별 방법 |
MX2022013662A (es) * | 2020-04-29 | 2023-02-01 | Abion Inc | Variante del interferon-beta humano con doble mutacion y metodo para mejorar la estabilidad de la variante del interferon-beta humano. |
WO2021221470A1 (ko) * | 2020-04-29 | 2021-11-04 | (주) 제노팜 | 인터페론-베타 변이체와 항체가 융합된 재조합 단백질 및 이를 포함하는 약학 조성물 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4966843A (en) * | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
DE4128319A1 (de) * | 1991-08-27 | 1993-03-04 | Bioferon Biochem Substanz | Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen |
DE19717864C2 (de) | 1997-04-23 | 2001-05-17 | Fraunhofer Ges Forschung | Humanes rekombinantes Interferon-beta, Verfahren zu seiner Herstellung und seine Verwendung |
US6514729B1 (en) * | 1999-05-12 | 2003-02-04 | Xencor, Inc. | Recombinant interferon-beta muteins |
US6531122B1 (en) * | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
JP4181543B2 (ja) * | 2002-08-31 | 2008-11-19 | シージェイチェイルジェダンコーポレーション | 糖鎖化ヒトインターフェロンアルファ同種体 |
WO2004031352A2 (en) * | 2002-10-01 | 2004-04-15 | Xencor, Inc. | Interferon variants with improved properties |
KR100541850B1 (ko) * | 2003-03-31 | 2006-01-11 | 삼성정밀화학 주식회사 | 인간 인터페론-베타 변이체 및 그의 제조방법 |
-
2004
- 2004-11-02 KR KR1020040088196A patent/KR100781666B1/ko active IP Right Grant
-
2005
- 2005-11-02 ES ES05804508T patent/ES2369088T3/es active Active
- 2005-11-02 PT PT05804508T patent/PT1809661E/pt unknown
- 2005-11-02 WO PCT/KR2005/003665 patent/WO2006049423A1/en active Application Filing
- 2005-11-02 AT AT05804508T patent/ATE509951T1/de active
- 2005-11-02 DK DK05804508.9T patent/DK1809661T3/da active
- 2005-11-02 EP EP05804508A patent/EP1809661B1/en active Active
- 2005-11-02 JP JP2007540249A patent/JP4637913B2/ja active Active
- 2005-11-02 BR BRPI0517932-7A patent/BRPI0517932B1/pt active IP Right Grant
- 2005-11-02 US US11/718,449 patent/US8101716B2/en active Active
- 2005-11-02 CN CN2005800452915A patent/CN101111519B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
BRPI0517932B1 (pt) | 2021-10-19 |
KR100781666B1 (ko) | 2007-12-03 |
PT1809661E (pt) | 2011-09-05 |
EP1809661A1 (en) | 2007-07-25 |
JP2008518631A (ja) | 2008-06-05 |
EP1809661B1 (en) | 2011-05-18 |
ES2369088T3 (es) | 2011-11-25 |
JP4637913B2 (ja) | 2011-02-23 |
BRPI0517932A (pt) | 2008-10-21 |
CN101111519B (zh) | 2012-11-07 |
WO2006049423A1 (en) | 2006-05-11 |
ATE509951T1 (de) | 2011-06-15 |
CN101111519A (zh) | 2008-01-23 |
KR20060039132A (ko) | 2006-05-08 |
DK1809661T3 (da) | 2011-09-05 |
US20100003721A1 (en) | 2010-01-07 |
EP1809661A4 (en) | 2008-02-06 |
US8101716B2 (en) | 2012-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0517932A8 (pt) | Muteína humana de beta-interferon, polinucleotídeo, vetor de expressão, célula animal, método para preparação de referida muteína e composição farmacêutica compreedendo a mesma | |
CY1122816T1 (el) | Στοχοθετημενοι συνδετικοι παραγοντες εναντι β7-η1 | |
MX2009010777A (es) | Composiciones de carne que comprenden productos de proteina estructurada con color. | |
CY1117312T1 (el) | Θεραπευτικη αγωγη συνουκλεϊνοπαθειων | |
MX2009010855A (es) | Composiciones de carne de pescados y mariscos que comprenden productos de proteina estructurada. | |
BRPI0516857A (pt) | dispositivos biomédicos que contêm copolìmeros de bloco anfifìlico | |
NO20083940L (no) | Fremgangsmater for redusering av proteinaggregering | |
BRPI0816097A2 (pt) | composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição. | |
BRPI0813311A2 (pt) | Composto, métodos para modulara a atividade de uma proteína quinase e para tratar câncer em um indivíduo, e, composição farmacêutica. | |
EA200802184A1 (ru) | Фармацевтические композиции с ингибиторами dpp iv | |
DK2227539T3 (da) | Sammensætning til menneske- og/eller dyreernæring, anvendelser deraf og gær | |
CR11795A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
DK3401327T3 (da) | Genprodukter med forskellig ekspression i tumorer og anvendelser deraf | |
NO20085420L (no) | Farmasøytisk formulering med fenylefrin og preparater for absorpsjon i tykktarmen | |
CO6680687A2 (es) | Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas | |
DK1765859T3 (da) | Annexiner, derivater deraf og annexin-cys varianter samt terapeutiske og diagnostiske anvendelser deraf | |
BRPI0517238A (pt) | formulações que compreendem ecteinascidina e um dissacarìdeo | |
BRPI0811193A2 (pt) | Proteína de ligação a antígeno isolada, ácido nucleico, célula recombinante, métodos para produzir uma proteína e para proteger ou tratar contra uma infecção por s. aureus em paciente, composição farmacêutica, uso da proteína de ligação a antígeno, e, polipeptídeo. | |
BRPI0809583A2 (pt) | polipeptídeos fgf-21 modificados e seus usos | |
BRPI0820956A2 (pt) | Composição nutricional enteral líquida, métodos para produzir a composição e para prover nutrição a uma pessoa em necessidade da mesma, e, uso simultâneo ou seqüêncial de caseína micelar e, opcionalmente, caseinato. | |
BRPI0506888A (pt) | composições de suplemento lìquido compreendendo um ou mais medicamentos | |
EA201170242A1 (ru) | Модифицированные бычьи полипептиды g-csf и их применение | |
BRPI0815576A2 (pt) | Método para produzir uma linha celular que produz uma proteína terapêutica, segunda linha celular transformada com uma segunda seqüência de polinucleotídeos, vetor, cassete de expressão amplificado, linha celular ou sua progênie, e, anticorpo. | |
BR112013019083A2 (pt) | combinação de (a) um imunoconjugado, composição farmacêutica, uso de (a) um imunoconjugado, método de tratamento de uma doença em um individuo, método de estímulo de função celular efetora em um indivíduo e kit destinado ao tratamento de uma doença. | |
BR112012011485A2 (pt) | "composições e métodos para tratar náusea e vômito centralmente mediados". |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: REFERENCEBIOLABS CO., LTD. (KR) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B25A | Requested transfer of rights approved |
Owner name: ABION INC. (KR) |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: DESPACHO: PARA QUE A PETICAO NO 870190036018 DE 15/04/2019 POSSA SER ACATADA COMO RECURSOAO ARQUIVAMENTO, O DEPOSITANTE DEVERA REALIZAR O PAGAMENTO DO VALOR DA RETRIBUICAO DEVIDA. |
|
B12C | Appeal against dismissal [chapter 12.3 patent gazette] | ||
B11T | Dismissal of application maintained [chapter 11.20 patent gazette] | ||
B11N | Dismissal: publication cancelled [chapter 11.14 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 11.20 NA RPI NO 2594 DE 24/09/2020 POR TER SIDO INDEVIDA. |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/11/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |